FDA approves Vivus' ED treatment

The Food and Drug Administration approved the fast-acting erectile dysfunction medication Stendra that was developed by Vivus Inc. (Nasdaq: VVUS) and Auxilium Pharmaceuticals Inc. (Nasdaq: AUXL). Shares of Vivus climbed 65 cents to $4.53 while Auxilium stock eased 14 cents to $31.04.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.